Evidence map›Paper›PMID 37416673›Full record

ArticleHeliyon2023

A method for improving the properties of famotidine.

Yongfeng Zhao, Ying Fan, Yan Zhang, Hong Xu, Min Li, Yunjie Zhu, Zhao Yang

Abstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Formulation and optimization of gastroretentive tablets containing famotidine in combination with antacids: In vitro evaluations and stability studies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Article
  3. Recent Advances in Oral Drug Delivery Systems for BCS III Drugs.Current issues in molecular biology · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongfeng ZhaoCollege of Pharmacy, Qingdao University, Qingdao, 266071, China.
Ying FanPharmacy Department, Qingdao Special Servicemen Recuperation Center of CPLA Navy, Qingdao, 266071, China.
Yan ZhangQingdao Institute for Food and Drug Control, Qingdao, 266073, China.
Hong XuShandong University of Science and Technology, Qingdao, 266590, China.
Min LiAnqiu People's Hospital, Weifang, 262199, China.
Yunjie ZhuQingdao Institute for Food and Drug Control, Qingdao, 266073, China.
Zhao YangCollege of Pharmacy, Qingdao University, Qingdao, 266071, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to crystal engineering, the pharmaceutical intermediate

Indexed as

Aqueous solubilityCrystal structureFamotidineM-nitrobenzoic acidPermeability

Identifiers

PMID37416673
PMCPMC10320128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.